- Question from MWhite: If hormones fuel ER/PR-positive breast cancer, what is fueling ER/PR-negative breast cancer?
- Answers - Kathy D. Miller, M.D. That's an excellent question, and one that is the focus of intense research. We have identified several growth factors that seem commonly expressed in ER/PR-negative and HER2-negative breast cancer. The most common of these is the epidermal growth factor receptor, or EGFR. There are several drugs in clinical trial that inhibit the EGFR. What we don't know yet is whether those drugs will be effective in this type of breast cancer.
On Wednesday, November 19, 2005, our Ask-the-Expert Online Conference was called Hormone-Receptor-Negative Breast Cancer. Kathy D. Miller, M.D., Marisa Weiss, M.D., and moderator Jennifer Armstrong, M.D. answered your questions about a wide range of issues related to hormone-receptor-negative breast cancer.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.